Administration moves to let pharmacies make popular unapproved peptides
Published
HHS sent the White House a plan that would let specialty pharmacies compound some peptides, such as BPC-157, that the FDA had restricted. FDA scientists have warned these injections lack solid safety evidence and carry risks like contamination and allergic reactions.
Source: Associated Press
This is a plain-language summary. Read the original source for full details.